



## Cutaneous side-effects of important oncology biologics- Cases Studies and literature review

The management of many metastatic malignancies has been revolutionised in recent years with the emergence of new biologics and refinements in protocols. These agents include checkpoint inhibitors, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, EGFR monoclonal antibody inhibitors, and rituximab amongst others.

These diverse agents have a range of toxicities that can impact significantly on patients, sometimes precluding further treatment. Cutaneous toxicities are not uncommon and can impact significantly on quality of life for these patients, sometimes requiring cessation of treatment. Dermatologists are increasingly required as part of the team managing these patients.

The oncological biologics relevant to dermatology will be briefly discussed including their therapeutic indications, biology, cutaneous toxicities and dermatological management. A number of interesting cases will be presented and discussion of the complex management required in patients with multiple comorbidities.

### References

1. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. Ransohoff JD, Kwong BY. *Clin Lymphoma Myeloma Leuk*. 2017 Dec;17(12):834–851. <https://doi.org/10.1016/j.clml.2017.07.005>. Epub 2017 Jul 14. Review. PMID: 28918995
2. Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy. Rzepecki AK, Cheng H, McLellan BN. *J Am Acad Dermatol*. 2018 Sep;79(3):545–555. <https://doi.org/10.1016/j.jaad.2018.04.046>. Epub 2018 May 4. Review. PMID: 29733938
3. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. *J Am Acad Dermatol*. 2015 Feb;72(2):221–36; quiz 237–8. <https://doi.org/10.1016/j.jaad.2014.07.033>. Review. PMID: 25592339
4. Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors. Erfan G, Puig S, Carrera C, Arance A, Gaba L, Victoria I, Garcia-Herrera A, Alos L, Malveyh J. *Acta Derm Venereol*. 2017 Feb 8;97(2):258–260. <https://doi.org/10.2340/00015555-2488>. No abstract available. PMID: 27353949
5. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R. *Clin Cancer Res*. 2016 Aug 15;22(16):4023–9. <https://doi.org/10.1158/1078-0432.CCR-15-2872>. Epub 2016 Mar 8. PMID.